Alvotech

What they do

Alvotech develops and manufactures biosimilars, which are biologic medical products highly similar to existing reference products. The company has a pipeline of biosimilar candidates targeting various therapeutic areas, including immunology, oncology, and ophthalmology. It operates through a network of subsidiaries and partners for commercialization in different regions.

Revenue drivers

• Biosimilar sales — Revenue from the sale of approved biosimilar products in various markets. The company has received regulatory approvals for several products, including AVT02 (adalimumab) and AVT04 (ustekinumab), which contribute to revenue.
• Licensing and collaboration agreements — Revenue from partnerships with pharmaceutical companies for the development and commercialization of biosimilars. For example, agreements with partners like Fujifilm Kyowa Kirin Biologics and STADA Arzneimittel provide upfront payments, milestones, and royalties.
• Contract development and manufacturing (CDMO) — Revenue from providing development and manufacturing services to third-party clients. Alvotech has CDMO capabilities and may generate fees from these services.

Recent performance

In fiscal year 2025, Alvotech reported revenue of USD 137.1 million, an increase from USD 65.4 million in 2024. The company's net loss narrowed to USD 41.2 million from USD 49.5 million in the prior year. The increase in revenue was driven by higher sales of AVT02 and AVT04, as well as licensing income from new partnerships. Cash and cash equivalents stood at USD 55.6 million as of December 31, 2025.

Strategy

Alvotech's strategy focuses on advancing its biosimilar pipeline, expanding commercial partnerships, and building manufacturing capabilities. The company plans to launch new biosimilars in key markets, including the U.S. and Europe. It is also investing in its manufacturing facilities to increase capacity and reduce costs. Management emphasizes differentiation through a portfolio of complex biosimilars and a global commercial network.

Risks

• Regulatory approval risk — Biosimilars require regulatory approval in each jurisdiction, and delays or failures could limit market entry and revenue potential.
• Competition from reference products and other biosimilars — Intense competition may affect pricing, market share, and profitability.
• Patent litigation risk — Alvotech is subject to patent challenges from reference product manufacturers, which could delay product launches and increase costs.
• Manufacturing and supply risk — Biological manufacturing is complex; any disruption or contamination could impact product supply and regulatory compliance.

Outlook

Management expects continued revenue growth driven by existing product sales and new launches. The company anticipates more regulatory approvals for its pipeline products in 2026. Cost controls and commercial execution remain priorities to achieve profitability. Cash requirements are expected to be funded through product sales, partnerships, and potential financing.